The ability of clinical microbiology laboratories to reliably detect carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) is an important element of the effort to prevent and contain the spread of these pathogens and an integral part of antimicrobial stewardship. All existing methods have limitations. A new, straightforward, inexpensive, and specific phenotypic method for the detection of carbapenemase production, the carbapenem inactivation method (CIM), was recently described. Here we describe a two-stage evaluation of a modified carbapenem inactivation method (mCIM), in which tryptic soy broth was substituted for water during the inactivation step and the length of this incubation was extended. A validation study was performed in a single clinical laboratory to determine the accuracy of the mCIM, followed by a nine-laboratory study to verify the reproducibility of these results and define the zone size cutoff that best discriminated between CP-CRE and members of the family Enterobacteriaceae that do not produce carbapenemases. Bacterial isolates previously characterized through whole-genome sequencing or targeted PCR as to the presence or absence of carbapenemase genes were tested for carbapenemase production using the mCIM; isolates with Ambler class A, B, and D carbapenemases, non-CP-CRE isolates, and carbapenem-susceptible isolates were included. The sensitivity of the mCIM observed in the validation study was 99% (95% confidence interval [95% CI], 93% to 100%), and the specificity was 100% (95% CI, 82% to 100%). In the second stage of the study, the range of sensitivities observed across nine laboratories was 93% to 100%, with a mean of 97%; the range of specificities was 97% to 100%, with a mean of 99%. The mCIM was easy to perform and interpret for Enterobacteriaceae, with results in less than 24 h and excellent reproducibility across laboratories.
T enem in the disk is degraded by the carbapenemase; in contrast, if the test microorganism does not produce carbapenemase, MEM retains its antimicrobial activity after incubation in the bacterial suspension. The disk is removed from the suspension and placed onto a Mueller-Hinton agar (MHA) plate seeded with a suspension of a carbapenem-susceptible indicator organism; following overnight incubation, the zone of inhibition is measured to determine whether the MEM had been hydrolyzed (growth of the indicator organism close to the disk), or is still active (a large zone of inhibition around the disk). The initial description of the CIM reported very promising results, including high sensitivity for the detection of a variety of carbapenemases and excellent specificity (24) . The test was straightforward to perform and interpret and involved low-cost materials already readily available in clinical laboratories (24) . Three early independent comparisons of the CIM to the Carba NP test found the CIM to be an accurate method for the detection of CP-CRE, with equal or better sensitivity for the detection of OXA-48-type carbapenemases in Enterobacteriaceae (25) (26) (27) . However, other investigations have found the CIM to have lower detection rates of the OXA-48-type carbapenemases, with reported sensitivities of 80%, 50%, and 91% ( Thomson, unpublished data). We, a CLSI working group, were charged with validating the performance of this modified carbapenem inactivation method (mCIM) in both a single-laboratory and multilaboratory evaluation.
RESULTS
Single-laboratory mCIM validation study. In the first stage of the study, 91 of the 92 isolates previously characterized as carrying carbapenemase genes gave positive results by mCIM, and all 23 isolates characterized as not carrying carbapenemase genes gave negative results by mCIM; there were no indeterminate results ( Table 1) . The single isolate with a false-negative result was an Enterobacter cloacae carrying bla for which the carbapenem MICs were low (FDA-CDC Antimicrobial Resistance Isolate Bank [AR Isolate Bank] no. 0050; Table 2 ). The sensitivity of the mCIM observed in this first stage of the study was 91/92 ϭ 99% (95% confidence interval [95% CI], 93% to 100%), and the specificity was 23/23 ϭ 100% (95% CI, 82% to 100%) compared to the genotype.
Receiver operating characteristic analysis to establish mCIM interpretive criteria. Using the zone diameter data from the multilaboratory study, the average sensitivity and specificity across all testing sites and the sum of average sensitivity and specificity that would be achieved by setting the positive mCIM cutoff criterion at all possible zone diameter values were calculated. The maximum sum of average sensitivity and specificity was found when defining a positive mCIM result as Յ18 mm and a negative mCIM result as Ն19 mm (see Table S2 in the supplemental material). Although this cutoff provided excellent separation between CP-CRE and those Enterobacteriaceae not producing carbapenemases, the CLSI working group recommended that an indeterminate interpretive range should be included in the testing procedure to prevent small, uncontrolled technical factors inherent to disk diffusion testing from causing major or very major errors. Therefore, a zone diameter of 6 to 15 mm was considered a positive result, a zone diameter of 16 to 18 mm was considered an indeterminate result (requiring further testing to establish the presence or absence of carbapenemase production), and a zone diameter of Ն19 mm was considered a negative result (Fig. 1) . When multiple small bacterial colonies were observed growing within the zone of inhibition around the disk, the mCIM results were classified as positive when the zone of confluent growth inhibition was Յ18 mm in diameter and as indeterminate when the zone was Ն19 mm in diameter (Fig. 2) . Analyzing the data from the first stage of the study using the original, provisional cutoff values and these revised criteria gave identical sensitivity and specificity results.
Nine-laboratory study of mCIM accuracy and reproducibility. The mCIM results from the second stage of the study are shown in Table 3 . These results include the mCIM results for the isolates tested during the multilaboratory accuracy and reproduc- ibility study, and for comparison, the CIM results from the single laboratory that performed both CIM and mCIM testing on each isolate concurrently. All quality control (QC) results were within the ranges at all sites. Out of the 27 isolates genetically characterized as carrying carbapenemase genes, 23 yielded mCIM-positive results in all nine laboratories and an additional 3 gave mCIM-positive results in eight of the nine laboratories; for the one remaining isolate, a Klebsiella pneumoniae carrying bla OXA-232 , a false-negative result was obtained by four laboratories. Among the 34 isolates genetically characterized as lacking carbapenemase genes, 32 had mCIM-negative results in all nine laboratories and the remaining two had mCIM-negative results in eight of the nine laboratories. The range of sensitivities observed across the nine laboratories (classifying indeterminate results as false-negative results when observed during the testing of isolates with known carbapenemase genes) was 93% to 100%, with a mean of 97%. The range of specificities across the nine laboratories (classifying indeterminate results as false-positive results when observed during the testing of isolates without carbapenemase genes) was 97% to 100%, with a mean of 99%. The laboratory that performed CIM and mCIM testing in parallel found the methods to be equally specific (100% [95% CI, 87% to 100%]), but the CIM to have a lower sensitivity (82% [95% CI, 61% to 93%]) than the mCIM (93% [95% CI, 74% to 99%]).
With the exception of a single isolate, discrepant results occurred in only one out of nine laboratories during the second stage of the study. Details about the isolates with discrepant results (and about repeat testing, where applicable) are shown in Table 2 . In the single laboratory that performed both CIM and mCIM testing, five isolates characterized as carrying carbapenemase genes had negative CIM results but positive mCIM results. These isolates with discrepant results included the following isolates: K. pneumoniae with bla OXA-232 (n ϭ 2; AR Isolate Bank no. 0066 and 0075), K. pneumoniae with bla OXA-181 (n ϭ 1; AR Isolate Bank no. 0039), K. pneumoniae with bla IMP-4 (n ϭ 1; AR Isolate Bank no. 0080), and Providencia rettgeri with bla NDM-1 (n ϭ 1; AR Isolate Bank no. 0082). . When multiple small bacterial colonies were observed growing within the zone of inhibition around the disk (C), the mCIM results were classified as positive when the outer zone of inhibition measured Յ15 mm in diameter and as indeterminate when the outer zone of inhibition measured Ն16 mm in diameter. d For isolates yielding discrepant results, a fresh subculture plate was created from the frozen stock, and the organism was subcultured twice before repeating mCIM testing. For those isolates with initially false-negative results, a MEM disk was placed between the first and second streak quadrants of the first subculture plate. Growth from around the disk was selected for the second subculture, and then the mCIM was repeated. ND, not done.
DISCUSSION
In our study, the mCIM exhibited excellent sensitivity for the detection of carbapenemase production among Enterobacteriaceae carrying a variety of different carbapenemase genes, including those belonging to Ambler classes A, B, and D. The assay was also highly specific, including when testing isolates meeting the 2015 CDC surveillance definition for CRE on the basis of mechanisms other than expression of carbapenemase genes (non-CP-CRE), such as ESBL production in combination with decreased outer membrane permeability, and when testing isolates with Ambler class C (AmpC-type) ␤-lactamases (both chromosomal and plasmid mediated). The mCIM was easy to perform and interpret for these enteric organisms, supported by overall excellent reproducibility of the results across nine testing sites. The mCIM uses inexpensive materials readily available in clinical microbiology laboratories at a cost of less than $1 per test, which is similar to the cost of MHT (Ͻ$1 per test), less than the cost of the Carba NP test ($2 to $10 per test) (21) , and substantially less than molecular methods (e.g., $55 per test [list price] for the Cepheid Xpert Carba-R, the only FDA-cleared test). After reviewing the data generated during this evaluation, the CLSI Subcommittee on Antimicrobial Susceptibility Testing voted to add the mCIM to the 27th edition of the CLSI Performance Standards for Antimicrobial Susceptibility Testing M100 Supplement (M100) as a reliable, standardized method available to laboratories that aim to identify CP-CRE for epidemiologic or infection control purposes or as additional testing for isolates with carbapenem MICs of Ն2 g/ml in laboratories that have not yet implemented the current CLSI or FDA carbapenem breakpoints (28) .
The two modifications of the original CIM that we implemented in our study were both changes to the carbapenem inactivation step: (i) using TSB instead of water, and (ii) extending the incubation time from 2 to 4 h. While our study did not directly compare the performance of the mCIM to the previously published CIM in all nine laboratories, the single site that did directly compare the two tests found the mCIM to . These data suggest that incubating the isolate and MEM disk in TSB and for 4 h enhance the detection of carbapenemases with either weaker hydrolytic activities, lower levels of expression, or metallo-␤-lactamases that require divalent cations for activity. Further studies would be necessary to separate the contributions of the growth medium versus water from the extended incubation time. Although we did not directly compare the performance of the mCIM to the MHT or the Carba NP test, we found the sensitivity of the mCIM for the detection of NDM carbapenemases and OXA-48-type carbapenemases to be higher than that reported in some evaluations of the MHT and Carba NP test, respectively (16) (17) (18) (19) (20) (21) . In addition, we saw very few false-positive mCIM results, including among Enterobacter spp. expressing AmpC ␤-lactamases, in contrast to what has been reported for the MHT (17) (18) (19) . Furthermore, at test sites where laboratory staff also had experience performing either the MHT, the Carba NP test, or both, the interpretation of mCIM results was thought to be less subjective and the mCIM to be simpler to perform.
One consideration for laboratories deciding which method to employ for screening CRE for carbapenemase production is that the mCIM, similar to the MHT, requires an overnight incubation with the indicator organism; this is in contrast to molecular methods and the Carba NP test, with which results can be generated within a single work shift. Additionally, a positive mCIM result does not provide information about the specific carbapenemase gene present in a given bacterial isolate, such as might be gleaned by the performance of a molecular test; nonetheless, the distinction between CP-CRE and non-CP-CRE may be sufficient to guide the stratification of infection control and antimicrobial stewardship interventions in many facilities. Furthermore, the results of mCIM testing might allow laboratories to consider restricting the utilization of molecular tests for specific carbapenemase genes to the subset of CRE that are shown to be CP-CRE by mCIM testing.
Our investigation has several limitations. We utilized isolates from an organism repository, rather than prospectively collected clinical isolates, such as those that would be tested by laboratories that implement the mCIM in routine clinical practice. However, this study design allowed for the inclusion of isolates with a representative spectrum of resistance mechanisms of interest, including those that might be encountered only rarely by clinical laboratories. If we had instead performed the mCIM on consecutively clinically recovered CRE and performed whole-genome sequencing to characterize them as to the presence or absence of carbapenemase genes, we would likely have included more non-CP-CRE and KPC-producing CRE and fewer NDM-, OXA-48-type-, VIM-, and IMP-producing CRE, which are currently less commonly isolated in U.S. clinical laboratories (29) . In addition, testing consecutive clinical isolates would have raised the likelihood that our evaluation would have included clonal, rather than unique, isolates, potentially limiting the generalizability of our results. Second, we did not systematically confirm preservation of resistance (either through antimicrobial susceptibility testing or genotypic testing) after thawing and subculturing isolates during the second stage of our study. Doing so would have aided in our ability to draw a Information about specific resistance mechanisms and carbapenem MICs for each isolate is provided in Table S1 in the supplemental material. b The modified carbapenem inactivation method (mCIM) zone diameters were classified as follows: 6 to 15 mm, positive (Pos); 16 to 18 mm, indeterminate (Ind); Ն19 mm, negative (Neg). When multiple small bacterial colonies were observed growing within the zone of inhibition around the disk, the mCIM results were classified as positive when the outer zone of inhibition measured Յ15 mm in diameter and as indeterminate when the outer zone of inhibition measured Ն16 mm in diameter. c The carbapenem inactivation method (CIM) results were classified as follows: no zone of inhibition present, positive (pos); any zone of inhibition present, negative (neg). d Details about the isolates with discrepant results (and about repeat testing, where applicable) are shown in Table 2 .
conclusions about the isolates that had false-negative mCIM results in one or more laboratories. A third limitation is that the specific individuals performing the testing may not have been blind to the whole-genome sequencing and PCR results of specific isolates. However, while measuring the size of zones of inhibition is subject to a small amount of variability, such measurements are sufficiently objective that the categorical interpretation of the mCIM should not be altered from positive to negative (or vice versa) by interreader differences, particularly with the inclusion of an indeterminate range in the method's interpretive criteria.
In the future, it will be important to evaluate the performance of the mCIM with additional Enterobacteriaceae isolates, including larger numbers with AmpC ␤-lactamases combined with porin alterations and larger numbers with OXA-48-type carbapenemases, since such isolates have challenged the performance of other phenotypic carbapenemase detection methods. Additionally, differentiation between carbapenem resistance mediated by carbapenemase production and that imparted by other mechanisms may be desirable for other bacteria (such as Pseudomonas aeruginosa and Acinetobacter baumannii complex) for epidemiologic or infection control purposes. The CLSI mCIM ad hoc working group is currently undertaking a study to explore this issue. While the current overnight incubation with the indicator organism prior to reading mCIM results is likely to be practical for many laboratories, determining whether results can be accurately interpreted at an earlier time point (such as after 6 h, as was reported in the original description of the CIM) would be of interest to laboratories in which the workflow would accommodate the performance of test steps on multiple work shifts. Finally, it would be interesting to further explore the impact of the presence of a carbapenem disk during the subculture of organisms prior to mCIM testing. We did not routinely include this step during our study because we sought to avoid extending the test procedure by an additional day, which would lengthen turnaround time in clinical laboratories. In addition, we thought that the inclusion of a carbapenem disk during subculture would be unlikely to improve the sensitivity of the method for the majority of CP-CRE. However, limited data (Table 2 ) generated during repeat testing of the three mCIM false-negative strains in the second stage of our study suggest that inclusion of a carbapenem disk during subculture might improve the already excellent sensitivity of the test for a subset of isolates. The mechanism by which this would occur (e.g., prevention of plasmid loss, selection of colonies with increased carbapenemase production, or even induction of carbapenemase production) is unknown, as is whether or not the inclusion of a carbapenem disk during subculture might adversely impact the specificity of the mCIM.
In conclusion, we found the mCIM to be a simple, inexpensive, accurate, and reproducible method for the identification of carbapenemase production among Enterobacteriaceae. The inclusion of the standardized mCIM procedure developed during this study in the widely used CLSI M100 document has the potential to facilitate the identification of CP-CRE in clinical laboratories, which may in turn aid facilities in understanding the local epidemiology of carbapenem resistance and serve as an important component of the critical, multifaceted effort to combat the spread of these pathogens.
MATERIALS AND METHODS
Bacterial isolates tested. During the first stage of the study, which was performed in a single laboratory (NorthShore University HealthSystem, Evanston, IL), a total of 117 members of the family Enterobacteriaceae representing 11 genera were used, including 107 from either the Gram-Negative Carbapenemase Detection Panel or the Enterobacteriaceae Carbapenemase Diversity Panel of the FDA-CDC Antimicrobial Resistance Isolate Bank (AR Isolate Bank; http://www.cdc.gov/drugresistance/ resistance-bank) and 10 from the UCLA Clinical Microbiology Laboratory (UCLA Medical Center, Los Angeles, CA). Each isolate had been previously characterized as to the presence or absence of carbapenemase genes, either by targeted PCR (n ϭ 6) or whole-genome sequencing (n ϭ 4) at UCLA as previously described (30) (31) (32) (33) (34) or by whole-genome sequencing at the CDC. At the CDC, antimicrobial resistance genes were detected using c-SSTAR (https://github.com/chrisgulvik/c-SSTAR), and a command line version of SSTAR (35) was used with a compatible ResFinder database (36) (accessed 25 October 2016). Reported resistance genes needed to meet a 99% sequence identity and 100% coverage threshold. Reported truncated outer membrane porin (OMP) genes, due to the presence of premature stop codons, had a Ն80% sequence identity and 100% coverage threshold. OMP genes were manually added to the ResFinder database (35) . Overall, 94 isolates were classified as carrying a variety of carbapenemase genes, and 23 isolates were characterized as lacking such genes (Table 1 and Table S1 in the supplemental material). Of the 117 isolates evaluated, 115 were ultimately included in the analysis because the previously identified carbapenemase gene (bla NDM in both cases) was not detected when molecular testing of two isolates was repeated at the CDC, possibly reflecting plasmid loss during subculture.
During the second stage of the study, which was conducted in nine different laboratories, a total of 61 Enterobacteriaceae representing 10 genera were used, all of which were obtained from the AR Isolate Bank; 27 had been classified as carrying carbapenemase genes, and 34 as lacking such genes (Table 3 and  Table S1 ). Among these 61 isolates, 50 had also been included in the first stage of the study and 11 had not; these 11 additional isolates, which were members of the Enterobacteriaceae Carbapenem Breakpoint Panel, were negative for carbapenemase genes. On the basis of phenotypic determination of reference broth microdilution MICs at the CDC (37), 14 of the 34 isolates without carbapenemase genes met the 2015 CDC surveillance definition of CRE, and 20 did not (15) .
The positive and negative quality control (QC) strains used in this study were Klebsiella pneumoniae ATCC BAA-1705 (bla KPC -positive by PCR) and Klebsiella pneumoniae ATCC BAA-1706, respectively (American Type Culture Collection, Manassas, VA).
From frozen (Ϫ80°C) stock, each isolate was subcultured twice on tryptic soy agar with 5% sheep blood (Trypticase soy agar with 5% sheep blood [TSA with 5% SB]; Becton, Dickinson and Company, Sparks, MD), incubating each subculture in ambient air at 35°C Ϯ 2°C for 18 to 24 h to ensure purity and viability before performance of the mCIM test.
Algorithm used for evaluation of mCIM. During the first stage of the study, mCIM testing was performed on each isolate. During the second stage, each of the nine participating laboratories performed mCIM testing on every isolate; in addition, one site simultaneously performed unmodified CIM testing (24) , with inoculum for both CIM and mCIM testing taken from the same subculture plate. All laboratories also performed mCIM testing on each QC strain on each day of testing. mCIM testing. Using a sterile inoculating loop, 1 l of test organism was added into a tube containing 2 ml of tryptic soy broth (TSB) (BD BBL tryptic soy broth or BD Bacto tryptic soy broth [Becton, Dickinson and Company, Sparks, MD] or Remel tryptic soy broth [Thermo Fisher Scientific, Inc., Waltham, MA]); the bacterial suspension was vortexed for 10 to 15 s. Next, a 10-g MEM disk (BD BBL Sensi-Disc susceptibility test disc) was aseptically added into the bacterial suspension. The tube was then incubated for 4 h Ϯ 15 min at 35°C Ϯ 2°C in ambient air. Just prior to completion of the 4-h carbapenem inactivation step, a suspension of the mCIM indicator organism (Escherichia coli ATCC 25922, a carbapenem-susceptible strain) with turbidity equivalent to a 0.5 McFarland standard was prepared, and the surface of a MHA plate (BD BBL Mueller-Hinton agar or Remel Mueller-Hinton agar) was inoculated using the procedure for standard disk diffusion susceptibility testing (38) . The meropenem (MEM) disk was then removed from the TSB bacterial suspension using a 10-l inoculating loop; the loop was dragged along the edge of the tube during removal to remove excess liquid, and the disk was placed on the inoculated MHA plate, which was then incubated in an inverted position for 18 to 24 h at 35°C Ϯ 2°C in ambient air. mCIM result interpretation. The diameter of the zone of inhibition around each MEM disk was measured (Fig. 3A) . During the first phase of the study, a zone diameter of 6 to 10 mm was considered a positive result (i.e., carbapenemase production detected), a zone diameter of 11 to 19 mm was considered an indeterminate result, and a zone diameter of Ն20 mm was considered a negative result (i.e., no carbapenemase production detected); these provisional cutoffs were chosen on the basis of the results of previously published studies that reported "uninhibited growth" of the indicator strain for CP-CRE (24, 25) and zone diameters of Ն20 mm for Enterobacteriaceae not producing carbapenemases (25) . A narrow ring of growth abutting the MEM disk, representing carryover of the test organism from the TSB, was ignored (Fig. 3B) . Analysis of the zone diameter data generated during the second phase of the study (which included results of testing performed by multiple individuals in multiple laboratories) informed the establishment of the ultimate, standardized interpretive criteria for the mCIM.
Statistical analysis. Data from the first stage of the study were used to calculate the sensitivity, specificity, and associated 95% confidence intervals for the mCIM, using genotypic testing (wholegenome sequencing or targeted PCR) as the reference method to which the performance of the mCIM was compared. Data from the second stage were used to calculate the sensitivity and specificity of the mCIM in each of the nine participating laboratories and the proportion of laboratories that observed the expected categorical result (positive or negative) for each isolate. Indeterminate mCIM results were classified as false-negative results when they occurred for isolates that carried carbapenemase genes and as false-positive results when they occurred for isolates that did not carry carbapenemase genes. Finally, the average overall sensitivity and average overall specificity generated by the application of each possible zone diameter cutoff value were calculated and used to determine an optimized cutoff value for the test through receiver operating characteristic analysis.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/JCM .00193-17.
SUPPLEMENTAL FILE 1, PDF file, 0.2 MB. SUPPLEMENTAL FILE 2, PDF file, 0.2 MB.
